News

British sciences gets £60m boost
Enlarge image

FundingUK

British sciences gets £60m boost

16.11.2012 - The British government plans to invest up to £60m in British universities. The ESRC will award up to £6m to chosen institutions.

"This investment I’m announcing today will help our leading universities become centres of innovation and entrepreneurship, generating commercial success to fuel growth“, stated Business Secretary Vince Cable. He hopes that the £60m investment in UK universities will help to create successful business from their research, improve industrial collaboration and foster greater entrepreneurship.

The announcement was made during Global Entrepreneurship Week. The funding comes from the Engineering and Physical Sciences Research Council (EPSRC), the UK’s main funding agency for scientific research. They will award Impact Acceleration Accounts ranging from £600k to £6m to 31 universities across the country. 

The funding will support the very early stage of turning research outputs into a commercial proposition – the valley of death between a research idea and developing it to a stage where a company or venture capitalist might be interested. It should help companies to engage with research projects at an earlier stage and benefit from research breakthroughs and the fundamental knowledge they generate. The funding will be used to support partnerships with SMEs and larger companies and take some of the risk out of their investment.

EPSRC chief executive Dave Delpy said: "The research we support is recognised as outstanding on the international stage. These awards aim to make a step change in the impact that it has on society: generating new business opportunities which drive economic growth, creating better, more informed public policy."

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-04/british-sciences-gets-pound60m-boost.html

BusinessSwitzerland

03.07.2015 Biotech giant Biogen is investing CHF 1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, the new plant will create up to 400 jobs.

R&DNetherlandsSpainAustria

02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

    FLOP

      TOP

        FLOP

          TOP

            FLOP

              No liability assumed, Date: 06.07.2015